ESMO updates ovarian carcinoma guidelines


  • Dawn O'Shea
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The European Society for Medical Oncology (ESMO) has published updated recommendations on the management of patients with relapsed epithelial ovarian carcinoma.

ESMO now recommends maintenance therapy with a poly-ADP-ribose-polymerase (PARP) inhibitor (olaparib, niraparib or rucaparib) following a response to platinum-based therapy in patients with recurrent platinum-sensitive high-grade ovarian cancer as a new standard of care option, irrespective of BRCA status.

For patients with recurrent platinum-sensitive ovarian cancer and a BRCA mutation who are unable to receive platinum-based therapy, rucaparib monotherapy is an option.

Announcing the eUpdate, ESMO commented: “Following the results of the first randomised maintenance trial with olaparib demonstrating a significant improvement in progression-free survival (PFS), particularly in patients with a BRCA mutation, further data has emerged and three other phase 3 trials with other PARP inhibitors have been conducted. The evidence shows that maintenance therapy with niraparib, rucaparib or olaparib (tablet formulation) after platinum-based chemotherapy for recurrent ovarian cancer has a wider clinical benefit.”

A PFS benefit is seen with all three drugs, not only in tumours with a BRCA mutation or a somatic mutation but also in BRCA wild-type tumours.